Cell Therapy: The Final Frontier for Treatment of Neurological Diseases
被引:19
|
作者:
Dutta, Susmita
论文数: 0引用数: 0
h-index: 0
机构:
Int Med Univ, Kuala Lumpur 57000, MalaysiaStempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Dutta, Susmita
[2
]
Singh, Gurbind
论文数: 0引用数: 0
h-index: 0
机构:
Stempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, MalaysiaStempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Singh, Gurbind
[1
]
Sreejith, Sailaja
论文数: 0引用数: 0
h-index: 0
机构:
Stempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, MalaysiaStempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Sreejith, Sailaja
[1
]
Mamidi, Murali Krishna
论文数: 0引用数: 0
h-index: 0
机构:
Stempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Manipal Univ, Manipal Inst Regenerat Med, Bangalore, Karnataka, IndiaStempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Mamidi, Murali Krishna
[1
,3
]
Husin, Juani Mazmin
论文数: 0引用数: 0
h-index: 0
机构:
Stempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, MalaysiaStempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Husin, Juani Mazmin
[1
]
Datta, Indrani
论文数: 0引用数: 0
h-index: 0
机构:
Manipal Univ, Manipal Inst Regenerat Med, Bangalore, Karnataka, IndiaStempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Datta, Indrani
[3
]
Pal, Rajarshi
论文数: 0引用数: 0
h-index: 0
机构:
Manipal Univ, Manipal Inst Regenerat Med, Bangalore, Karnataka, IndiaStempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Pal, Rajarshi
[3
]
Das, Anjan Kumar
论文数: 0引用数: 0
h-index: 0
机构:
Stempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, MalaysiaStempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
Das, Anjan Kumar
[1
]
机构:
[1] Stempeut Res Malaysia Sdn Bhd, Kuala Lumpur 57000, Malaysia
[2] Int Med Univ, Kuala Lumpur 57000, Malaysia
[3] Manipal Univ, Manipal Inst Regenerat Med, Bangalore, Karnataka, India
Cell transplantation and clinical trials;
Neural differentiation;
Neurorepair;
Stem cells;
MESENCHYMAL STEM-CELLS;
MARROW STROMAL CELLS;
NEURAL PROGENITOR CELLS;
BONE-MARROW;
DIRECT CONVERSION;
NEURONAL DIFFERENTIATION;
DOPAMINERGIC-NEURONS;
CORD BLOOD;
EXPERIMENTAL STROKE;
HUMAN FIBROBLASTS;
D O I:
10.1111/cns.12027
中图分类号:
Q189 [神经科学];
学科分类号:
071006 ;
摘要:
Neurodegenerative diseases are devastating because they cause increasing loss of cognitive and physical functions and affect an estimated 1 billion individuals worldwide. Unfortunately, no drugs are currently available to halt their progression, except a few that are largely inadequate. This mandates the search of new treatments for these progressively degenerative diseases. Neural stem cells (NSCs) have been successfully isolated, propagated, and characterized from the adult brains of mammals, including humans. The confirmation that neurogenesis occurs in the adult brain via NSCs opens up fresh avenues for treating neurological problems. The proof-of-concept studies demonstrating the neural differentiation capacity of stem cells both in vitro and in vivo have raised widespread enthusiasm toward cell-based interventions. It is anticipated that cell-based neurogenic drugs may reverse or compensate for deficits associated with neurological diseases. The increasing interest of the private sector in using human stem cells in therapeutics is evidenced by launching of several collaborative clinical research activities between Pharma giants and research institutions or small start-up companies. In this review, we discuss the major developments that have taken place in this field to position stem cells as a prospective candidate drug for the treatment of neurological disorders.